Bihua Chen has bought stock on 10 days since Apr 2021
Director at BlossomHill Therapeutics, Inc., and 5 other companies
SEC CIK 0001599214 · Filings on SEC.gov ↗
Bihua Chen's record
3 months after each buy, from the first price a copier could get.
8 buys since 2021 with 3 months of prices.
Companies
Every filing
11 filings since Apr 2021, newest first
BlossomHill Therapeutics, Inc.
Director
Helix Acquisition Corp. III
Chair, CEO and 10% owner
Helix Acquisition Corp. II
CEO, Chair and 10% owner
Moonlake Immunotherapeutics
10% owner
Moonlake Immunotherapeutics
10% owner
Biomea Fusion, Inc.
Director and 10% owner
Moonlake Immunotherapeutics
10% owner
Moonlake Immunotherapeutics
10% owner
Erasca, Inc.
Director
Erasca, Inc.
Director
Biomea Fusion, Inc.
Director
About Bihua Chen
Bihua Chen is the Founder and CEO of Cormorant Asset Management, LP, a healthcare-focused investment firm managing over $3 billion in assets across public and private funds specializing in biotech, medtech, and life sciences.( She serves as Chairperson and CEO of Helix Acquisition Corp. III (HLXC), a special purpose acquisition company (SPAC) sponsored by Helix Holdings III LLC, an affiliate of Cormorant, which completed its IPO in January 2026 raising $172.5 million to pursue mergers in healthcare-related industries.(
Chen has a proven track record in SPACs, leading prior vehicles like Helix Acquisition Corp. II, which merged with BridgeBio Oncology Therapeutics (BBOT) in August 2025, and Helix Acquisition Corp., which merged with MoonLake Immunotherapeutics (MLTX) in April 2022.( She holds directorships at companies including Nexo Therapeutics, Inc., nChroma Bio, Atia Vision, Inc., and Blossomhill Therapeutics, Inc., and is a director at BridgeBio Oncology Therapeutics.( As a corporate insider, Chen recently traded in HLXC, holding significant influence through her roles in related funds and entities.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.